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ABSTRACT
The human T cell lymphotropic virus type 1 (HTLV-1) is the first human retrovirus 
discovered. Since then, it has spread worldwide and is mainly associated with adult T cell 
leukemia/lymphoma (ATLL) and HTLV1-associated myelopathy (HAM). Its relationship, 
however, with other types of cancer is controversial. We describe the case of a patient 
presenting with small cells lung epidermoid carcinoma who had recently developed HAM, and 
a review of the literature related to these conditions. This is the first case of this type of lung 
cancer, the same of the first description in the literature, associated with HAM outside Japan. 
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INTRODUCTION
The infection by the human T cell lymphotropic virus type 1 (HTLV-1) may 
cause several lymphoproliferative disorders, such as adult T cell leukemia/lymphoma 
(ATLL), one of the classic presentations of this infection. Its relationship, however, 
with other types of cancer is controversial and described in the literature by case 
reports or small case series. Matsuzaki et al.1, in 1990, described for the first time 
in the literature the association of non-ATLL neoplasia and HTLV-1 infection, a 
small cells type of lung cancer (SCLC) in Japan.
Lung cancer is the most frequent malignant tumor and has the highest mortality 
among all neoplasias. In 2012, 1.8 million new cases of lung cancer were diagnosed 
worldwide and 1.59 million deaths were recorded2. This cancer is classified into 
SCLC, the same described by Matsuzaki et al.1 and is our patient’s type of cancer, 
with an overall 5-year survival rate of 6% and non-SCLC, with rates from 14 to 17%3. 
Several oncogenic factors are related to the tumorigenic process, involved 
in the dysregulation of apoptosis, leading to uncontrolled cell proliferation and 
angiogenesis, in addition to chronic inflammatory and infectious states3. Risk 
factors for its development are cigarette smoking, exposure to high air pollution 
environments, exposure to radiation, genetic predisposition, among others2. As 
the patient described in our case was a smoker, this is a confounding factor in the 
etiology of his lung cancer.
CASE PRESENTATION
A male patient, 60 years old, a previous drug user and cigarette smoker, 
was evaluated for the first time at the HTLV clinic in October 2017, when the 
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HTLV-1 infection was confirmed, but he was aymptomatic 
at that time. The magnetic resonance imaging (MRI) 
of the thoracic spine showed a diffuse spinal atrophy 
with widening of the central canal, despite the absence 
of symptoms, and evidencing a myelopathy on the 
neurological examination, with a positive Babinski’s sign 
on the right side. In March 2018, he was re-evaluated 
and had developed some weakness of the left lower limb 
accompanied by urinary incontinence. The neurologic 
examination revealed a proximal muscle weakness, grade 
4 in the lower limbs, with spasticity and evident pyramidal 
signs, tetra hyperreflexia and presence of the Babinski 
sign. The HTLV-1 proviral load (PVL) was 47 copies/
mL and the T-cell proliferation (LPA) test was 1,148 cpm. 
At that time, he underwent a lumbar puncture to collect 
the cerebrospinal fluid (CSF), that showed 20 cells/mm3 
(85% lymphocytes and 15% monocytes), protein 47 
mg/dL, glucose 37 mg/dL, lactic acid 17 mg/dL, and a 
negative oncological cytology. These conditions evolved 
over a time period of four months leading to dyspnea, dry 
cough and weight loss. In July 2018, the weakness of his 
lower limbs got worse as the urinary incontinence. He 
was undernourished, had mild dry cough and dyspnea. 
He was sent to the emergency department of the hospital 
and a chest X-ray (Figure 1) showed opacity of the left 
hemithorax and a deviation of the trachea. The chest 
tomography showed an image suggestive of pulmonary 
neoplasia and the anatomopathological exams (Figure 2) 
and immunohistochemistry (Figure 3) of the pulmonary 
lesion confirmed the presence of small cells lung 
epidermoid carcinoma. He progressed rapidly to death 
after one month after hospital admission due to respiratory 
failure. There was no specific treatment, only palliative 
care measures to minimize his suffering.
Figure 1 - Chest X Ray: opacity of the left hemithorax, with 
tracheal deviation.
Figure 2 - Microscopic appearance of the lung tumour cells 
stained by Hematoxylin-eosin. Islands of large polygonal 
malignant squamous cells (x100 magnification).
Figure 3 - A complementary immunohistochemistry exam 
showing nuclear positivity for the P63 protein that can 
differently stain Small Cells Lung Epidermoid Carcinoma 
(x 400 magnification).
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DISCUSSION
In 1990, Matsuzaki et al.1 described a 58-year-old 
man with SCLC and a monoclonal integration of HTLV-
1 proviruses within DNA from the cancer cells was 
demonstrated. Besides that, the serum of this patient 
contained high levels of interleukin-2 receptors (IL2-R), 
and it was demonstrated that the SCLC cells from this 
patient were also positive for IL2-R. It is known that these 
receptors are expressed only on lymphoid cells4-6, so the 
author concluded that it is possible that HTLV-1 had induced 
the expression of IL2-R on the surface of SCLC cells, that 
are non-hematopoietic malignant cells. As described by 
Inoue et al.7 in 1986, a viral product encoded by the pX 
sequence of HTLV-1, called p4Ox, can induce the IL2-R 
gene expression on T-cells.
In addition, still on this type of neoplasia, Nomori et al.8 
studied serum anti-HTLV-1 antibodies among 212 lung 
cancer patients without symptoms of HTLV-1 infection 
and found eight (4%) positive cases: six were bronchiolo-
alveolar carcinomas and two were adenocarcinomas with 
a bronchiolo-alveolar carcinoma component.
Asou et al.9, in 1986, observed five cases of neoplasia 
among 18 patients with a smoldering type of ATLL, such 
as cancer of the vagina, skin, stomach, and liver, and 
Kozuru  et  al.10 showed an increased risk of neoplasia 
(lung, uterine cervix, uterine corpus, breast, pharynx, 
esophagus, salivary glandand brain) in patients with 
ATLL, their mothers and siblings, in comparison with 
HTLV1-seronegative non-Hodgkin’s lymphoma (NHL) 
patients, their siblings and their mothers. 
Regarding the gynecological cancer, Miyazaki et al.11 
reported that in women with cervical or vaginal carcinoma, 
the rate of tumor recurrence was significantly higher in those 
with HTLV1-positive serology. Oncogenic mechanisms 
that can be related to HTLV-1 influence the prognosis of 
these patients. Later, in 1995 in Jamaica, Strickler et al.12 
found that in patients with cervical intraepithelial neoplasia 
grade 3 (CIN III) or invasive cancer of the uterine cervix, 
the seroprevalence of HTLV-1 was greater than among 
controls with low grade neoplasia or a non-characteristic 
abnormality with benign cervical pathology.
Despite these data, Hirata et al.13 analyzed 699 patients 
with cancer aged 50 years and older, diagnosed between 
1991 and 2004 in Japan, and 1,365 controls without cancer. 
The prevalence of HTLV-1 infection in gastric cancer 
patients was significantly lower than in control patients 
without any neoplasia13. They have also found that the 
prevalences of HTLV-1 infection in patients infected 
by Helicobacter pylori (H. pylori) and controls without 
gastroduodenal disease were different, of 9.3% and 17.8%, 
respectively. Data reporting HTLV-1 and this bacterium 
have also been also described by Isomoto et al.14, who found 
a lower prevalence of H. pylori in individuals with HTLV-1 
infection in comparison with non-infected-HTLV-1 patients, 
and HTLV-1 infection reductions when patients were at risk 
of H. pylori infection and proliferation, reducing the risk 
of gastric cancer.
H. pylori is a known risk factor for gastric cancer and 
there are some evidences, described in these studies, that 
HTLV-1 modulates the immune response against H. pylori, 
therefore, reducing the risk of the latter15. On the contrary, 
Hirata et al.13 concluded that the HTLV-1 infection was 
not associated with an increased or reduced risk of other 
non-gastric cancers. This was corroborated by the study of 
Arisawa et al.16, who found no increment in the overall risk 
of developing other non-ATLL neoplasias, but a reduction in 
the risk of gastric cancer in patients with HTLV-1 infections. 
Tahaei et al.17 studied the relationship between gastric 
cancer and HTLV-1 infection in Iran, and the same result 
was found, with a lower prevalence of HTLV-1 infections 
among patients with gastric cancer. 
Arisawa et al.18 evaluated the risk of cancer in HTLV1- 
infected individuals over a period of 15.4 years and 
showed no association with an increased risk of developing 
cancer, excluding ATLL. However, the risk of liver cancer, 
hepatocellular carcinoma (HCC) in 86% of cases, was 2.1-
fold higher among HTLV-1 carriers than in non-carriers18. 
Firstly, this can be explained by the high rates of co-infection 
of HTLV-1 and HCV, due to the same route of infection, 
that is sexual or vertical transmission from mothers to their 
fetuses; or via contaminated organic fluids. Subsequent 
interactions between HCV and HTLV-1 are possible and the 
synergistic effect of these co-infections was evaluated in a 
study performed in Miyazaki city in Japan19.
Stuver et al.20 have also assessed the relationship 
between liver cancer and HTLV-1. Between 1984 and 1993, 
there were 10 deaths from liver cancer, and five of them 
had anti-HTLV-1 antibodies. However, this co-infection 
does not appear to have impacted the increased risk of 
mortality due to liver cancer associated with the presence 
of anti-HCV antibodies. 
Hirata et al.21 evaluated clinical and pathological factors 
in breast cancer patients and their relationship with HTLV-1 
infection. There was no clinical or pathological aspect in 
this cancer related to HTLV-1, including the disease-free 
time and total survival, unless the patients infected with 
HTLV-1 were older.
Several studies demonstrated the relationship of viral 
proteins that can induce the oncogenesis. In respect to 
ATLL, the transformation of normal T lymphocytes into 
infected T cells is made by an oncoprotein called Tax, 
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encoded by HTLV-122. The infected T cells are subjected to 
genomic instability caused by the Tax-mediated inhibition 
of cellular DNA repair pathways and increased mutations in 
the cell genome23. Regarding tumors in humans, more than 
half of them have a mutation in the p53 protein, whose gene, 
the TP53, is located on chromosome 17p13.124. This is a 
tumor suppressor protein that induces cell death by means 
of apoptosis in cells that have undergone an oncogenic 
stress25. Thus, the progression to malignancy depends on 
this loss of the p53gene function25.
Zane et al.22 carried out a study with genetically 
modified mice to demonstrate that the relationship between 
the Tax protein and the p53 gene function would be 
inactivated by Tax. It has been shown that inactivation of 
the p53 gene by Tax occurs, but it is less significant than the 
inactivation that takes place through genetic mutation. It was 
also reported that the wild-type p53-induced phosphatase 1 
(Wip1) contributes to Tax in this inhibition22.
Wip1 is a human protein phosphatase discovered in 1997 
by Fiscella et al.26 that is amplified and overexpressed in 
several human cancers. This protein, in a p53- gene dependent 
manner, might contribute to the growth suppression induced 
in response to DNA damage. In addition to the proteins 
already mentioned, in 2002 the HTLV-1 bZIP factor (HBZ) 
was identified, a novel basic leucine zipper factor. HBZ 
is consistently expressed in all ATL cases, unlike Tax, 
whose expression may be lost during the course of the 
infection27. HBZ also plays an essential role in oncogenesis, 
by mechanisms not yet well known, that contribute to the 
development and continued growth of cancer28.
CONCLUSION
The correlation between HTLV-1 infection and other 
cancers than ATLL is still controversial in the literature, 
especially due to the small amount of published studies on 
the subject. We described here the case of a patient with 
HTLV-1 infection and a lung cancer type that coincides with 
the first description in the literature of a non-ATLL cancer 
associated with HTLV-1. Both, the clinical evolution of lung 
cancer and the HAM progressed rapidly, in less than one 
year, which may indicate the interplay of immunological 
and genetic factors of these two conditions. Further and 
broader studies are needed to elucidate this association, 
within a systematic clinical classification perspective that 
can encompass the full spectrum of primary and secondary 
complications associated with HTLV-1 infection.
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